Cargando…
Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study
Onabotulinumtoxin A (onabotA) has shown efficacy in chronic migraine (CM), with good tolerability and a low rate of adverse effects, most of them not severe. The aim of this study is to evaluate tolerability and adverse effects of onabotA in clinical practice and to analyze if there is a relationshi...
Autores principales: | García-Azorín, David, Martínez, Blanca, Gutiérrez, María, Ruiz-Piñero, Marina, Echavarría, Ana, Sierra, Álvaro, Guerrero, Ángel L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783903/ https://www.ncbi.nlm.nih.gov/pubmed/36548746 http://dx.doi.org/10.3390/toxins14120850 |
Ejemplares similares
-
Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study
por: Sánchez-Rodríguez, Carmen, et al.
Publicado: (2021) -
Onabotulinum Toxin A (Botox®) in the Treatment of Neurogenic Bladder Overactivity
por: Rohrsted, Malene, et al.
Publicado: (2012) -
Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations
por: Barbanti, Piero, et al.
Publicado: (2017) -
The Role of Onabotulinum Toxin Type A in the Management of Chronic Non-migraine Headaches
por: Jia, Cassie, et al.
Publicado: (2019) -
Onabotulinum toxin A vs. incobotulinum toxin A for the treatment of chronic migraine: a retrospective review
por: Lucchese, Scott, et al.
Publicado: (2023)